---
title: "Yifang Biotech's Psoriasis Treatment Receives FDA Phase II Trial Approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279566692.md"
description: "Yifang Biotech has received FDA approval for a Phase II clinical trial of its psoriasis treatment, D-2570, as a monotherapy. The application reached the 30-day default period without objections, confirming the trial's approval under relevant regulations."
datetime: "2026-03-18T09:22:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279566692.md)
  - [en](https://longbridge.com/en/news/279566692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279566692.md)
generator: "portal-rs"
---

# Yifang Biotech's Psoriasis Treatment Receives FDA Phase II Trial Approval

Yifang Biotech has announced that its application to the U.S. Food and Drug Administration (FDA) for a Phase II clinical trial of D-2570 as a monotherapy for psoriasis (PsO) has reached the 30-day default period without any objections from the FDA. According to Jin10, this means that the Phase II clinical trial for D-2570 as a monotherapy for PsO in the United States has officially been approved, in accordance with relevant regulations.

### Related Stocks

- [688382.CN](https://longbridge.com/en/quote/688382.CN.md)

## Related News & Research

- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [Inhalation Sciences to present FDA-funded DissolvIt evaluation results at respiratory drug development conferences](https://longbridge.com/en/news/296444383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**